| Literature DB >> 27375767 |
Barbara Schober-Halper1, Marlene Hofmann1, Stefan Oesen1, Bernhard Franzke1, Thomas Wolf2, Eva-Maria Strasser3, Norbert Bachl2, Michael Quittan3, Karl-Heinz Wagner4, Barbara Wessner5.
Abstract
BACKGROUND: Ageing, inactivity and obesity are associated with chronic low-grade inflammation contributing to a variety of lifestyle-related diseases. Transforming growth factor-β (TGF-β) is a multimodal protein with various cellular functions ranging from tissue remodelling to the regulation of inflammation and immune functions. While it is generally accepted that aerobic exercise exerts beneficial effects on several aspects of immune functions, even in older adults, the effect of resistance training remains unclear. The aim of this study was to investigate whether progressive resistance training (6 months) with or without nutritional supplementation (protein and vitamins) would influence circulating C-reactive protein and TGF-β levels as well as TGF-β signalling in peripheral mononuclear cells (PBMCs) of institutionalised adults with a median age of 84.5 (65.0-97.4) years.Entities:
Keywords: Chronic inflammation; Inflammageing; Strength training; TGF-β pathway; Vienna Active Ageing Study (VAAS); microRNA
Year: 2016 PMID: 27375767 PMCID: PMC4929754 DOI: 10.1186/s12979-016-0077-9
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Fig. 1Participant flow
Baseline characteristics
| All ( | CT ( | RT ( | RTS ( |
| |
|---|---|---|---|---|---|
| Gender [female/male] | 77/11 | 25/5 | 28/4 | 24/2 | 0.602 |
| Age [years] | 84.5 (65.0–97.4) | 84.5 (69.4–97.4) | 84.4 (71.7–93.2) | 84.3 (65.0–92.2) | 0.864 |
| BMI [kg/m2] | 28.9 (18.1–50.0) | 29.8 (18.1–36.9) | 28.2 (22.7–40.2) | 27.9 (22.9–50.0) | 0.741 |
| Obesity [n (%)] | 32 (36.8 %) | 14 (46.7 %) | 8 (25.0 %) | 10 (35.7 %) | 0.235 |
| Hyperlipidaemia [n (%)] | 32 (36.4 %) | 9 (30.0 %) | 10 (31.3 %) | 13 (46.4 %) | 0.226 |
| Diabetes Type II [n (%)] | 14 (15.9 %) | 6 (20 %) | 7 (21.9 %) | 1 (3.6 %) | 0.132 |
| Hypertension [n (%)] | 70 (79.5 %) | 26 (86.7 %) | 27 (84.4 %) | 17 (60.7 %) | 0.100 |
| Cardiac diseases [n (%)] | 27 (30.7 %) | 12 (40.0 %) | 9 (28.1 %) | 6 (21.4 %) | 0.362 |
| Osteoporosis [n (%)] | 35 (39.8 %) | 12 (40.0 %) | 12 (37.5 %) | 11 (39.3 %) | 0.933 |
| History of cancer [n (%)] | 12 (13.6 %) | 5 (16.7 %) | 4 (12.5 %) | 3 (10.7 %) | 0.833 |
| Leukocyte subpopulations and circulating biomarkers | |||||
| Leukocytes [x109 cells/L] | 6.6 (3.3–13.0) | 7.4 (4.9–10.3)* | 5.8 (3.1–9.8) | 6.9 (4.4–13.3)* |
|
| Lymphocytes [cells/μl] | 1990 (930–4930) | 1985 (910–3510) | 1835 (830–3330) | 2200 (1460–4700) | 0.085 |
| Neutrophils [cells/μl] | 3695 (1530–9860) | 4414 (2410–6630)* | 2931 (1530–6800) | 3889 (2370–9860) |
|
| Eosinophils [cells/μl] | 200 (10–740) | 225 (36–620) | 160 (10–740) | 220 (10–470) | 0.135 |
| Basophils [cells/μl] | 40 (10–111) | 45 (10–111) | 35 (10–190) | 35 (10–90) | 0.397 |
| Monocytes [cells/μl] | 560 (250–910) | 587 (72–950) | 520 (260–860) | 545 (320–960) | 0.189 |
| hs-CRP [mg/L] | 1.95 (0.3–7.9) | 2.1 (0.5–7.9) | 1.9 (0.3–7.6) | 1.9 (0.6–6.7) | 0.918 |
| TGF-β [μg/L] | 33.3 (16.7–73.7) | 38.2 (18.7–73.7) | 32.8 (16.7–55.4) | 32.1 (21.0–51.2) | 0.083 |
| PBMC gene expression | |||||
| TGF-β/GAPDH [-] | 0.85 (0.06–3.36) | 0.48 (0.23–2.66) | 0.60 (0.21–2.52) | 0.58 (0.06–3.36) | 0.725 |
| TGF-βRI/GAPDH [-] | 2.05 (0.14–28.82) | 1.99 (0.14–22.39) | 2.04 (0.69–19.25) | 2.11 (0.29–28.81) | 0.990 |
| TGF-βRII/GAPDH [-] | 1.67 (0.51–15.85) | 1.54 (0.66–7.79) | 1.60 (0.66–14.85) | 1.79 (0.51–10.80) | 0.714 |
| miRNA–21 [copies/pg] | 2400 (57–4720) | 2920 (343–4500) | 2120 (57–4720) | 2350 (550–4590) | 0.765 |
Data are expressed as medians (min–max); Group differences were detected using X 2 or Kruskal–Wallis tests and if significant, followed by Bonferroni-corrected post-hoc analyses (*p < 0.05 vs. RT); significant differences are marked in bold
Abbreviations: CT cognitive training, RT resistance training, RTS resistance training plus supplement, PBMC peripheral blood mononuclear cell, hs-CRP high sensitive C-reactive protein, TGF-β transforming growth factor-β, TGF-βR TGF-β receptor, GAPDH glyceraldehyde 3-phosphate dehydrogenase, miR-21 microRNA-21
Baseline differences between drop-outs and finishers
| Total ( | Dropouts ( | Non-Dropouts ( |
| |
|---|---|---|---|---|
| Gender [female/male] | 77/11 | 18/3 | 59/8 | 0.777 |
| Age [years] | 84.5 (65.0–97.4) | 85.2 (69.4–92.2) | 84.2 (65.0–97.4) | 0.282 |
| BMI [kg/m2] | 28.9 (18.1–50.0) | 28.3 (18.1–43.7) | 30.7 (23.4–50.0) | 0.094 |
| hs-CRP [mg/L] | 1.9 (0.3–7.9) | 2.0 (0.8–7.9) | 1.9 (0.3–7.6) | 0.413 |
| TGF-β signalling | ||||
| TGF-β [μg/L] | 33.3 (16.7–73.7) | 39.3 (22.5–58.0) | 32.8 (16.7–73.7) | 0.178 |
| TGF-β/GAPDH [-] | 0.53 (0.06–3.36) | 1.07 (0.21–3.36) | 0.52 (0.06–2.66) |
|
| TGF-β RI/GAPDH [-] | 2.05 (0.14–28.81) | 6.41 (1.31–28.81) | 1.90 (0.14–22.39) |
|
| TGF-β RII/GAPDH [-] | 1.67 (0.51–14.85) | 3.00 (0.91–10.80) | 1.59 (0.51–14.85) | 0.099 |
| miR–21 [copies/pg RNA] | 2400 (57–5720) | 979 (498–3640) | 2815 (57–4720) |
|
| Co-morbidities | ||||
| Obesity [n (%)] | 32 (36.4 %) | 10 (47.6 %) | 22 (32.8 %) | 0.162 |
| Hyperlipidemia [n (%)] | 32 (36.4 %) | 3 (14.2 %) | 29 (43.3 %) |
|
| Diabetes Type II [n (%)] | 14 (15.9 %) | 3 (14.3 %) | 11 (16.4 %) | 0.816 |
| Hypertension [n (%)] | 70 (79.5 %) | 17 (81.0 %) | 53 (79.1 %) | 0.855 |
| Cardiac diseases [n (%)] | 27 (30.7 %) | 7 (33.3 %) | 20 (29.9 %) | 0.763 |
| Osteoporosis [n (%)] | 35 (39.8 %) | 9 (42.9 %) | 26 (38.8 %) | 0.741 |
| History of cancer [n (%)] | 12 (13.6 %) | 3 (14.3 %) | 9 (13.4 %) | 0.921 |
Data for continuous variables are shown as medians (min–max). For co-morbidities, the respective numbers of affected participants were determined at the medical entrance examination. Obesity was defined as a BMI of >30 kg/m2. Differences between groups were determined by Mann–Whitney U or X 2 tests; significant differences are marked in bold
Intervention effects on leukocyte subpopulations and circulating inflammatory markers
| Baseline ( | 3 months ( | 6 months ( |
| |
|---|---|---|---|---|
| Leukocytes [x109 cells/L] | ||||
| CT ( | 7.2 (4.9–10.3)** | 7.2 (4.1–11.9) | 7.1 (5.4–9.4) | 0.440 |
| RT ( | 5.6 (3.1–9.1) | 6.0 (3.2–8.9) | 6.0 (3.3–9.8)* |
|
| RTS ( | 7.0 (4.4–13.3)** | 7.2 (4.5–11.7)** | 7.1 (4.7–13.0) | 0.586 |
| Lymphocytes [cells/μl] | ||||
| CT ( | 1985 (910–3510) | 2090 (890–3980) | 2250 (930–3540) | 0.387 |
| RT ( | 1675 (830–3330) | 1765 (912–3190) | 1720 (1010–3430) | 0.651 |
| RTS ( | 2255 (1460–4700) | 2340 (1570–4680) | 2190 (1640–4930) | 0.810 |
| Monocytes [cells/μl] | ||||
| CT ( | 610 (72–950) | 550 (300–780) | 590 (400–910) | 0.534 |
| RT ( | 520 (260–790) | 475 (250–960) | 510 (250–880) | 0.104 |
| RTS ( | 585 (320–960) | 490 (300–840) | 545 (330–900) | 0.404 |
| Neutrophils [cells/μl] | ||||
| CT ( | 4300 (2410–6630)** | 4010 (1990–7420) | 3910 (3110–5880) | 0.247 |
| RT ( | 2876 (1530–6800) | 3390 (1720–5880) | 3520 (1800–7330)* |
|
| RTS ( | 4030 (2430–9860) | 3930 (1720–8730) | 4290 (1664–8680) | 0.368 |
| Basophils [cells/μl] | ||||
| CT ( | 40 (20–111) | 30 (10–90) | 30 (20–100) |
|
| RT ( | 35 (10–90) | 30 (10–100) | 30 (10–80) | 0.878 |
| RTS ( | 40 (10–90) | 40 (10–90) | 40 (10–80) | 0.344 |
| Eosinophils [cells/μl] | ||||
| CT ( | 210 (36–448) | 170 (80–470) | 220 (90–330) | 0.911 |
| RT ( | 160 (10–690) | 186 (40–530) | 200 (80–570) | 0.381 |
| RTS ( | 248 (90–470) | 195 (20–630) | 260 (90–650) | 0.137 |
| hs-CRP [mg/L] | ||||
| CT ( | 2.0 (0.5–4.8) | 2.4 (0.2–5.5) | 1.8 (0.3–8.5) | 0.424 |
| RT ( | 1.9 (0.3–7.6) | 2.4 (0.5–7.7) | 2.0 (0.6–9.6) | 0.645 |
| RTS ( | 1.8 (0.6–5.4) | 2.1 (0.6–8.5) | 1.6 (0.4–5.5) | 0.135 |
| TGF-β [μg/L] | ||||
| CT ( | 36.0 (18.7–73.7) | 39.8 (18.4–67.8) | 40.8 (21.9–67.9) | 0.953 |
| RT ( | 31.5 (16.7–50.0) | 34.5 (18.3–59.7) | 34.6 (12.7–57.3) | 0.075 |
| RTS ( | 33.7 (21.0–51.2) | 38.0 (22.9–50.5) | 35.5 (22.1–52.1) | 0.431 |
Data are expressed as medians (min–max); Differences over the time course were detected using the Friedman test and if significant, followed by Bonferroni-corrected post-hoc analyses (* p < 0.05 vs. baseline within respective study group). Differences between groups were analysed by Kruskal Wallis test, followed by Bonferroni-corrected post-hoc analyses (** p < 0.05 vs. RT group within respective time point; significant differences are marked in bold)
Abbreviations: CT cognitive training, RT resistance training, RTS resistance training plus supplement, hs-CRP high sensitive C-reactive protein, TGF-β transforming growth factor-β
Intervention effects on TGF-β signalling gene expression
| Baseline ( | 3 months ( | 6 months ( |
| |
|---|---|---|---|---|
| TGF-β/GAPDH [-] | ||||
| CT ( | 0.47 (0.23–2.66) | 0.47 (0.27–4.10) | 0.44 (0.25–1.93) | 0.772 |
| RT ( | 0.54 (0.26–2.30) | 0.52 (0.16–2.63) | 0.52 (0.23–2.30) | 0.568 |
| RTS ( | 0.55 (0.06–1.63) | 0.45 (0.15–2.20) | 0.56 (0.09–1.32) | 0.692 |
| TGF-βRI/GAPDH [-] | ||||
| CT ( | 1.99 (0.14–22.39) | 1.62 (0.46–29.89) | 1.97 (0.11–9.24) | 0.717 |
| RT ( | 1.87 (0.69–9.54) | 1.61 (0.34–9.21)* | 1.77 (0.54–15.91) |
|
| RTS ( | 1.95 (0.30–8.63) | 1.63 (0.28–8.59) | 2.38 (0.52–6.73) | 0.801 |
| TGF-βRII/GAPDH [-] | ||||
| CT ( | 1.54 (0.66–7.79) | 1.39 (0.68–9.17) | 1.48 (0.67–6.32) | 0.827 |
| RT ( | 1.60 (0.66–14.86) | 1.59 (0.57–13.50) | 1.67 (0.63–8.79) | 0.296 |
| RTS ( | 1.58 (0.51–5.13) | 1.73 (0.44–3.98) | 1.95 (0.69–4.73) | 0.331 |
| miRNA-21 [copies/pg RNA] | ||||
| CT ( | 3163 (343–4500) | 2840 (276–5120) | 2460 (1050–4700) | 0.861 |
| RT ( | 2602 (57–4720) | 2340 (758–5600) | 2540 (330–5020) | 0.368 |
| RTS ( | 2536 (845–4590) | 2535 (353–4780) | 2810 (1600–4630) | 0.854 |
Data are expressed as medians (min–max); Differences were detected using the Friedman test and if significant, followed by Bonferroni-corrected post-hoc analyses (* p < 0.05 vs. baseline; significant differences are marked in bold)
Abbreviations: CT cognitive training, RT resistance training, RTS resistance training plus supplement, TGF-β transforming growth factor-β, TGF-βR TGF-β receptor, GAPDH glyceraldehyde 3-phosphate dehydrogenase, miR-21 microRNA-21
Association between physical performance at baseline and the response of TGF-β-related parameters
| Baseline performance | |||||
|---|---|---|---|---|---|
| Handgrip strength | Chair stand test | Arm lifting test | 6-MWT | ||
| Change (difference between 3 months and baseline) | Circulating TGF-β | -0.039 |
|
|
|
| TGF-β/GAPDH | 0.103 | 0.220 | -0.051 | 0.199 | |
| TGF-β RI/GAPDH | 0.222 | 0.222 | -0.148 | 0.148 | |
| TGF-β RII/GAPDH | 0.142 |
| -0.027 | 0.204 | |
| miRNA-21 | 0.201 | 0.143 | -0.029 | 0.038 | |
Data indicate Spearman-Rho correlation coefficients. * p < 0.05 (significant correlations are marked in bold)